97 related articles for article (PubMed ID: 10087397)
1. Estramustine reversal of resistance to intravesical epirubicin chemotherapy.
Jennings AM; Solomon LZ; Sharpe P; Hayes MC; Cooper AJ; Birch BR
Eur Urol; 1999 Apr; 35(4):327-35. PubMed ID: 10087397
[TBL] [Abstract][Full Text] [Related]
2. Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer.
Harris NM; Duffy PM; Crook TJ; Anderson WR; Sharpe P; Hayes MC; Cooper AJ; Solomon LZ
BJU Int; 2002 Dec; 90(9):957-64. PubMed ID: 12460364
[TBL] [Abstract][Full Text] [Related]
3. Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study.
Duffy PM; Hayes MC; Gatrell SK; Cooper A; Smart CJ
Br J Urol; 1996 Jun; 77(6):824-9. PubMed ID: 8705215
[TBL] [Abstract][Full Text] [Related]
4. Time-lapse live cell imaging and flow analysis of multidrug resistance reversal by verapamil in bladder cancer cell lines.
Featherstone JM; Lwaleed BA; Speers AG; Hayes MC; Birch BR; Cooper AJ
Urology; 2009 Aug; 74(2):378-84. PubMed ID: 19501884
[TBL] [Abstract][Full Text] [Related]
5. Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model.
Duffy PM; Hayes MC; Cooper A; Smart CJ
Br J Urol; 1996 Jun; 77(6):819-23. PubMed ID: 8705214
[TBL] [Abstract][Full Text] [Related]
6. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines.
Featherstone JM; Speers AG; Lwaleed BA; Hayes MC; Cooper AJ; Birch BR
BJU Int; 2005 May; 95(7):1091-8. PubMed ID: 15839939
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance in a urothelial cancer cell line after 3, 1-hour exposures to mitomycin C.
Speers AG; Lwaleed BA; Featherstone JM; Cooper AJ
J Urol; 2007 Nov; 178(5):2171-5. PubMed ID: 17870115
[TBL] [Abstract][Full Text] [Related]
8. Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma.
Harris NM; Anderson WR; Lwaleed BA; Cooper AJ; Birch BR; Solomon LZ
Cancer; 2003 Jan; 97(1):71-8. PubMed ID: 12491507
[TBL] [Abstract][Full Text] [Related]
9. Progesterone: a novel adjunct to intravesical chemotherapy.
Lewin J; Cooper A; Birch B
BJU Int; 2002 Nov; 90(7):736-41. PubMed ID: 12410758
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance in a urothelial cancer cell line after 1-hour mitomycin C exposure.
Birare N; Lwaleed BA; Cooper AJ
J Urol; 2009 Nov; 182(5):2472-6. PubMed ID: 19765756
[TBL] [Abstract][Full Text] [Related]
11. Furosemide reverses multidrug resistance status in bladder cancer cells in vitro.
Speers AG; Lwaleed BA; Featherstone JM; Sallis BJ; Cooper AJ
J Clin Pathol; 2006 Sep; 59(9):912-5. PubMed ID: 16556663
[TBL] [Abstract][Full Text] [Related]
12. Water as a tumoricidal agent in bladder cancer. In vitro studies in parental and resistant cell lines.
Solomon LZ; Birch BR; Cooper AJ
Eur Urol; 1998 Dec; 34(6):500-4. PubMed ID: 9831792
[TBL] [Abstract][Full Text] [Related]
13. Delayed high-dose intravesical epirubicin therapy of superficial bladder cancer. A way to reduce the side effects and increase the efficacy--a phase 2 trial.
Bassi P; Spinadin R; Longo F; Saraeb S; Pappagallo GL; Zattoni F; Pagano F
Urol Int; 2002; 68(4):216-9. PubMed ID: 12053020
[TBL] [Abstract][Full Text] [Related]
14. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
15. Localization of anthracycline accumulation in sensitive and resistant urothelial tumor cell lines.
Davies CL; Duffy PM; MacRobert AJ; Loizidou MC; Cooper AJ; Taylor I
Cancer Detect Prev; 1996; 20(6):625-33. PubMed ID: 8939349
[TBL] [Abstract][Full Text] [Related]
16. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml.
Kuroda M; Niijima T; Kotake T; Akaza H; Hinotsu S;
Eur Urol; 2004 May; 45(5):600-5. PubMed ID: 15082202
[TBL] [Abstract][Full Text] [Related]
17. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes.
Liu B; Wang Z; Chen B; Yu J; Zhang P; Ding Q; Zhang Y
Cancer Invest; 2006 Mar; 24(2):160-3. PubMed ID: 16537185
[TBL] [Abstract][Full Text] [Related]
19. Role of P-glycoprotein in chemoresistant superficial bladder tumours.
Nargund VH; Lowe J; Flannigan GM; Hamilton Stewart PA
Eur Urol; 1997; 31(2):160-2. PubMed ID: 9076458
[TBL] [Abstract][Full Text] [Related]
20. Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent?
Solomon LZ; Jennings AM; Foley SJ; Birch BR; Cooper AJ
Br J Urol; 1998 Jul; 82(1):122-6. PubMed ID: 9698674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
